Pharmaceuticals

Cellular Immunotherapy Market to Grow at a CAGR of 13.9% from 2025 to 2029

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Are The Current (2025) And Forecast (2029) Sizes Of The Cellular Immunotherapy Market?

The cellular immunotherapy market has shown significant growth in recent years. Its value is projected to rise from $5.72 billion in 2024 to $6.56 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 14.7%. This historical expansion can be linked to advancements in cancer treatment, successful clinical outcomes, regulatory endorsements, and an increasing prevalence of targeted conditions.

The cellular immunotherapy market size is projected to experience rapid expansion in the coming years. It is anticipated to reach “$11.03 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 13.9%. This projected growth during the forecast period is driven by factors such as the expansion into solid tumors, advancements in manufacturing processes, improvements in healthcare infrastructure, and increased research funding. Key developments anticipated in this period include investments in research and development, emerging clinical trial data, and the rise of combination therapies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3435&type=smp

Which Drivers Are Supporting Growth Of The Cellular Immunotherapy Market?

The cellular immunotherapy market is anticipated to grow throughout the forecast period, fueled by advancements in research and positive outcomes from clinical trials in cellular immunotherapy. Companies are concentrating their efforts on creating novel cellular immunotherapies designed to address various diseases. An example of this focus is a report released in June 2022 by the Cancer Research Institute, a US-based nonprofit organization devoted solely to developing immunotherapy for the prevention, treatment, and eventual eradication of all cancers. This report indicated that as of April 2022, the worldwide immuno-oncology pipeline featured 2,756 active cell therapy drugs. This represents a 36% increase from the 2,031 agents identified in the 2021 landscape analysis, though the growth rate slightly moderated compared to the 43% seen in the prior year. The significant acceleration in cellular immunotherapy development across clinical and preclinical stages in 2020, relative to 2019, is expected to broaden the overall scope of cellular immunotherapy, consequently yielding increased revenues and contributing to the growth of the cellular immunotherapy market.

How Is The Cellular Immunotherapy Market Classified Into Different Segments?

The cellular immunotherapy market covered in this report is segmented –

1) By Therapy: Tumor-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy

2) By Primary Indication: B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin lymphoma, Other Primary Indications

3) By Application: Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumor, Lung Cancer, Other Applications

Subsegments:

1) By Tumour-Infiltrating Lymphocyte (TIL) Therapy: Autologous TIL Therapy, Allogeneic TIL Therapy, Other TIL Therapy

2) By Engineered T Cell Receptor (TCR) Therapy: Alpha-Beta TCR Therapy, Gamma-Delta TCR Therapy, Other Engineered TCR Therapy

3) By Chimeric Antigen Receptor (CAR) T Cell Therapy: Autologous CAR T Cell Therapy, Allogeneic CAR T Cell Therapy, CAR T Cell Therapy For Solid Tumors, CAR T Cell Therapy For Hematologic Malignancies, Other CAR T Cell Therapy

4) By Natural Killer (NK) Cell Therapy: Autologous NK Cell Therapy, Allogeneic NK Cell Therapy, NK Cell Therapy With Engineered Modifications, Other NK Cell Therapy

How Are Emerging Market Trends Shaping The Cellular Immunotherapy Industry Landscape?

Companies in the cellular immunotherapy market are increasingly concentrating on developing off-the-shelf allogeneic therapies to provide new and improved cancer treatments. These allogeneic therapies are generated from donor cells, unlike autologous therapies which use the patient’s own cells. Their non-customized nature offers advantages such as enhanced cost-effectiveness, the potential for large-scale and swift production, and streamlined quality control. For example, in May 2022, Novartis AG, a Switzerland-based pharmaceutical company focused on drug discovery, development, manufacturing, and commercialization, reported that the US Food and Drug Administration (FDA) had granted expedited approval for Kymriah (tisagenlecleucel) for adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) who have received two or more lines of systemic therapy. Furthermore, Acepodia, a US-based next-generation cell immuno-technology company, initiated a phase 1 clinical trial in August 2020 to assess ACE1702, an allogeneic, off-the-shelf NK cell therapy, for treating solid tumors.

Which Industry Leaders Are Driving Innovation Across The Cellular Immunotherapy Market?

Major companies operating in the cellular immunotherapy market include Novartis International AG, Gilead Sciences Inc., Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co. Ltd, Green Cross Corp, AstraZeneca plc, Bristol Myers Squibb Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Adicet Bio Inc., ResTORbio Inc., Celyad SA, Merck KGaA, GlaxoSmithKline plc., Johnson & Johnson, Adaptimmune Therapeutics plc, AVROBIO Inc., Cellular Biomedicine Group Inc., Kite Pharma Inc., Juno Therapeutics Inc., Celgene Corporation, Bluebird Bio Inc., Tmunity Therapeutics Inc., Atara Biotherapeutics Inc., Fate Therapeutics Inc., Precision Biosciences Inc., Allogene Therapeutics Inc., CRISPR Therapeutics AG, Sangamo Therapeutics Inc., Intellia Therapeutics Inc., Editas Medicine Inc., Caribou Biosciences Inc., Mammoth Biosciences Inc., Synthego Corporation

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report

Which Regional Markets Are Contributing Most To The Cellular Immunotherapy Industry Expansion?

North America was the largest region in the cellular immunotherapy market in 2024. The regions covered in the cellular immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Cellular Immunotherapy Market Report:

https://www.thebusinessresearchcompany.com/customise?id=3435&type=smp

Browse Through More Reports Similar to the Global Cellular Immunotherapy Market 2025, By The Business Research Company

Drugs For Immunotherapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/drugs-for-immunotherapy-global-market-report

Skin Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/skin-cancer-drugs-global-market-report

Colorectal Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/colorectal-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795